

## 雑 誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
恩地森一, 錢谷幹男, 山本和秀, 坪内博仁	自己免疫性肝炎の診断指針・治療指針 (2013年)	肝臓	54	723-725	2013
Yamamoto K, Miyake Y, Ohira H, Suzuki Y, Zeniya M, Onji M, Tsubouchi H; Intractable Liver and Biliary Diseases Study Group of Japan.	Prognosis of autoimmune hepatitis showing acute presentation.	Hepato Res	42	630-638	2012
Ohira H, Abe K, Takahashi A, Zeniya M, Ichida T.	Clinical features of hepatocellular carcinoma in patients with autoimmune hepatitis in Japan.	J Gastroenterol	48	109-114	2012
Nakano M, Saeki C, Takahashi H, Homma S, Tajiri H, Zeniya M.	Activated natural killer T cells producing interferon-gamma elicit promoting activity to murine dendritic cell-based autoimmune hepatic inflammation.	Clin Exp Immunol	170	274-282	2012
Zeniya M, Takahashi H.	Diagnostic criteria of autoimmune hepatitis-Historical review and present problem.	Jikeikai Med J	58	89-93	2011
錢谷幹男	自己免疫性肝炎の診断・治療における最近の知見	最新医学	67	1811-1816	2012
Matsumoto K, Miyake Y, Umeda Y, Matsushita H, Matsuda H, Takaki A, Sadamori H, Nouse K, Yagi T, Fujiwara T, Yamamoto K.	Serial changes of serum growth factor levels and liver regeneration after partial hepatectomy in healthy humans.	Int J Mol Sci	14	20704-28	2013
三宅康広, 松本和幸, 大西敦之, 松下浩志, 高木章乃夫, 山本和秀	自己免疫性肝胆膵疾患の病態解明の進歩 自己免疫性肝炎における新規自己抗体	消化器と免疫	49	3-6	2013
阿部雅則, 恩地森一	肝胆膵疾患; 予後の変遷 自己免疫性肝炎の予後	肝胆膵	66	447-453	2013
阿部雅則, 恩地森一	肝臓治療学 自己免疫性肝疾患の治療学	細胞	45	223-231	2013
阿部雅則, 恩地森一	自己免疫性疾患・アレルギー疾患(後編)それぞれの疾患の理解 自己免疫性肝炎	最新医学	68	1335-1343	2013
Abe M, Hiasa Y, Onji M.	T helper 17 cells in autoimmune liver diseases.	Clin Dev Immunol	2013	607073	2013
Migita K, Nakamura M, Abiru S, Jiuchi Y, Nagaoka S, Komori A, Hashimoto S, Bekki S, Yamasaki K, Komatsu T, Shimada M, Kouno H, Hijioka T, Kohjima M, Nakamura M, Kato M, Yoshizawa K, Ohta H, Nakamura Y, Takezaki E, Nishimura H, Sato T, Ario K, Hirashima N, Oohara Y, Naganuma A, Muro T, Sakai H, Mita E, Sugi K, Yamashita H, Makita F, Yatsuhashi H, Ishibashi H, Yasunami M.	Association of STAT4 polymorphisms with susceptibility to type-1 autoimmune hepatitis in the Japanese population.	PLoS One	8(8)	e71382	2013

Kanno Y, Watanabe H, Takahashi A, Abe K, <u>Hira H</u>	Anti-phosphoenolpyruvate carboxykinase 2 antibody in patients with autoimmune hepatitis.	Hepatol Res		In press	
Kamimura K, Imai M, Sakamaki A, Mori S, Kobayashi M, Mizuno KI, Takeuchi M, Suda T, Nomoto M, <u>Aoyagi Y.</u>	Granulocytapheresis for the treatment of severe alcoholic hepatitis: a case series and literature review.	Dig Dis Sci	59(2)	482-88	2014
Osaki A, Suda T, Kamimura K, Tsuchiya A, Tamura Y, Takamura M, Igarashi M, Kawai H, Yamagiwa S, <u>Aoyagi Y.</u>	A safe and effective dose of cisplatin in hepatic arterial infusion chemotherapy for hepatocellular carcinoma.	Cancer Med	2	86-98	2013
Kamimura K, Suda T, Zhang G, <u>Aoyagi Y.</u> , Liu D.	Parameters affecting image-guided, hydrodynamic gene delivery to swine liver.	Mol Ther Nucleic Acids	2	e128	2013
Takeuchi M, Kobayashi M, Hashimoto S, Mizuno K, Kawaguchi G, Sasamoto R, Aoyama H, <u>Aoyagi Y.</u>	Salvage endoscopic submucosal dissection in patients with local failure after chemoradiotherapy for esophageal squamous cell carcinoma.	Scand J Gastroenterol	48	1095-101	2013
Kobayashi Y, Kamimura K, Nomoto M, Sugitani S, <u>Aoyagi Y.</u>	Immunohistochemical character of hepatic angiomyolipoma: for its management.	Case Rep Med	2013	298143	2013
Suda T, Nagashima A, Takahashi S, Kanefuji T, Kamimura K, Tamura Y, Takamura M, Igarashi M, Kawai H, Yamagiwa S, Nomoto M, <u>Aoyagi Y.</u>	Active treatments are a rational approach for hepatocellular carcinoma in elderly patients.	World J Gastroenterol	19	3831-40	2013
Yamada K, Suda T, Komoro YS, Kanefuji T, Kubota T, Murayama T, Nakayama H, <u>Aoyagi Y.</u>	Low fat intake is associated with pathological manifestations and poor recovery in patients with hepatocellular carcinoma.	Nutr J	12	79	2013
Matsuda Y, Wakai T, Kubota M, Takamura M, Yamagiwa S, <u>Aoyagi Y.</u> , Osawa M, Fujimaki S, Sanpei A, Genda T, Ichida T.	Clinical significance of cell cycle inhibitors in hepatocellular carcinoma.	Med Mol Morphol	46	185-92	2013
Tamura Y, Suda T, Ariei S, Sata M, Moriyasu F, Imamura H, Kawasaki S, Izumi N, Takayama T, Kokudo N, Yamamoto M, Iijima H, <u>Aoyagi Y.</u>	Value of highly sensitive fucosylated fraction of alpha-fetoprotein for prediction of hepatocellular carcinoma recurrence after curative treatment.	Dig Dis Sci	58	2406-12	2013
Yano M, Ohkoshi S, Aoki YH, Takahashi H, Kurita S, Yamazaki K, Suzuki K, Yamagiwa S, Sanpei A, Fujimaki S, Wakai T, Kudo SE, Matsuda Y, <u>Aoyagi Y.</u>	Hepatitis B virus X induces cell proliferation in the hepatocarcinogenesis via up-regulation of cytoplasmic p21 expression.	Liver Int	33	1218-29	2013

Matsuda Y, Wakai T, Kubota M, Osawa M, Takamura M, Yamagiwa S, <u>Aoyagi Y</u> , Sanpei A, Fujimaki S.	DNA damage sensor $\gamma$ -H2AX is increased in preneoplastic lesions of hepatocellular carcinoma.	Scientific World Journal	2013	597095	2013
Sato M, Matsuda Y, Wakai T, Kubota M, Osawa M, Fujimaki S, Sanpei A, Takamura M, Yamagiwa S, <u>Aoyagi Y</u> .	P21-activated kinase-2 is a critical mediator of transforming growth factor- $\beta$ -induced hepatoma cell migration.	J Gastroenterol Hepatol	28	1047-55	2013
Yokoo T, Kamimura K, Suda T, Kanefuji T, Oda M, Zhang G, Liu D, <u>Aoyagi Y</u> .	Novel electric power-driven hydrodynamic injection system for gene delivery: safety and efficacy of human factor IX delivery in rats.	Gene Ther	20	816-23	2013
Ikarashi S, Nishikura K, Ajioka Y, <u>Aoyagi Y</u> .	Re-evaluation of phenotypic expression in undifferentiated-type early gastric adenocarcinomas using mucin core protein and CDX2.	Gastric Cancer	16	208-19	2013
Yamashita T, <u>Honda M</u> , <u>Nakamoto Y</u> , Baba M, Nio K, Hara Y, Zeng SS, Hayashi T, Kondo M, Takatori H, Yamashita T, Mizukoshi E, Ikeda H, Zen Y, Takamura H, Wang XW, Kaneko S.	Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma.	Hepatology	57(4)	1484-1497	2013
Arihara F, Mizukoshi E, Kitahara M, Takata Y, Arai K, Yamashita T, <u>Nakamoto Y</u> , Kaneko S.	Increase in CD14+HLA-DR <sup>-</sup> /low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis.	Cancer Immunol Immunother	62(8)	1421-1430	2013
Maruoka R, Aoki N, Kido M, Iwamoto S, Nishiura H, Ikeda A, Chiba T, <u>Watanabe N</u> .	Splenectomy prolongs the effects of corticosteroids in mouse models of autoimmune hepatitis.	Gastroenterology	145	209-220	2013
Imai N, Ikeda K, Seko Y, Matsumoto N, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, <u>Suzuki Y</u> , Arase Y, Kumada H.	Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and chronic renal failure.	Nihon Shokakibyō Gakkai Zasshi	108(11)	1872-8	2011
Hiramatsu N, Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, <u>Suzuki Y</u> , Sugauchi F, Tamori A, Kakinnuma S, Matsuura K, Izumi N.	Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis.	J Gastroenterol	46(9)	1111-9	2011
Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, <u>Suzuki Y</u> , Hiramatsu N, Sugauchi F, Tamori A, Nakagawa M, Izumi N.	Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis.	J Med Virol	83(3)	445-52	2011

保坂哲也, 鈴木文孝, 小林正宏, 瀬古裕也, 今井則博, 平川美晴, 川村祐介, 瀬崎ひとみ, 芥田憲夫, 鈴木義之, 斎藤聡, 荒瀬康司, 池田健次, 小林万利子, 熊田博光	B型慢性肝疾患に対する核酸アナログ療法による HBs 抗原消失とその関連因子の検討	肝臓	52(4)	255-7	2011
Suzuki F, Arase Y, Suzuki Y, Akuta N, Sezaki H, Seko Y, Kawamura Y, Hosaka T, Kobayabashi M, Saitoh S, Ikeda K, Kobayashi M, Kumada H.	Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan.	J Gastroenterol	47	814-822	2012
Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Wenhua Hu, Timothy Eley, McPhee F, Eric Hughes, Kumada H.	Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.	J Hepatol	58	655-662	2013
Toyota J, Ozeki I, Karino Y, Asahina Y, Izumi N, Takahashi S, Kawakami Y, Chayama K, Kamiya N, Aoki K, Yamada I, Suzuki Y, Suzuki F, Kumada H.	Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b.	J Viral Hepat	20	167-173	2013
Hirakawa M, Ikeda K, Kobayashi M, Kawamura Y, Hosaka T, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Saitoh S, Arase Y, Kumada H.	Randomized controlled trial of a new procedure of radiofrequency ablation using an expandable needle hepatocellular carcinoma.	Hepatol Res	43	846-852	2013
Suzuki F, Suzuki Y, Sezaki H, Akuta N, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Mineta R, Watahiki S, Kobayashi M, Nakayasu Y, Tsuda H, Aoki K, Yamada I, Kumada H.	Exploratory Study on telaprevir given every 8h at 500mg or 750mg with peginterferon-alpha-2b and rivavirin in hepatitis C patients.	Hepatol Res	43	691-701	2013
Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.	Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.	Hepatology	58	98-107	2013

Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, <u>Suzuki Y</u> , Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Emergence of Telaprevir-Resistant Variants Detected by Ultra-Deep Sequencing After Triple Therapy in Patients Infected With HCV Genotype 1.	J Med Virol	85	1028-1036	2013
Kawamura Y, Saitoh S, Arase Y, Ikeda K, Fukushima T, Hara T, Seko Y, Hosaka T, Kobayashi M, Sezaki H, Akuta N, Suzuki F, <u>Suzuki Y</u> , Fukuzawa K, Hamada Y, Takahashi J, Kobayashi M, Kumada H.	Three-dimensional magnetic resonance imaging for stringent diagnosis of advanced fibrosis associated with nonalcoholic steatohepatitis.	Hepatol Int	7	850-858	2013
Seko Y, Ikeda K, Kawamura Y, Fukushima T, Hara T, Sezaki H, Hosaka T, Akuta N, Suzuki F, Kobayashi M, <u>Suzuki Y</u> , Saitoh S, Arase Y, Kumada H.	Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma.	Hepatol Res	43	942-949	2013
Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, <u>Suzuki Y</u> , Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H	Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study.	J Gastroenterol	48	930-941	2013
Akuta N, Suzuki F, Fukushima T, Kawamura Y, Sezaki H, <u>Suzuki Y</u> , Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Prediction of Treatment Efficacy and Telaprevir-Resistant Variants after Triple Therapy in Patients Infected with HCV Genotype 1.	J Clin Microbiol	51	2862-2868	2013
Suzuki F, Hosaka T, <u>Suzuki Y</u> , Akuta N, Sezaki H, Hara T, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H.	Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine.	J Gastroenterol		In press	
Akuta N, Suzuki F, Fukushima T, Kawamura Y, Sezaki H, <u>Suzuki Y</u> , Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Utility of detection of telaprevir-resistant variant for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection.	J Clin Microbiol	52	193-200	2014

Arase Y, Kobayashi M, Kawamura Y, Suzuki F, <u>Suzuki Y</u> , Akuta N, Kobayashi M, Sezaki H, Saito S, Hosaka T, Ikeda K, Kumada H, Kobayashi T.	Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C.	J Med Virol	86	169-175	2014
Akuta N, Suzuki F, Kobayashi M, Hara T, Sezaki H, <u>Suzuki Y</u> , Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kumada H.	Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis.	J Med Virol	86	131-138	2014
Kawakami Y, Ikeda K, Fukushima T, Hara T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, <u>Suzuki Y</u> , Arase Y, Kumada H.	Potential of no-touch pincer ablation procedure for small hepatocellular carcinoma that uses a multipolar radiofrequency ablation system: an experimental animal study.	Hepatol Res		In press	
Kawamura Y, Ikeda K, Fukushima T, Seko Y, Hara T, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, <u>Suzuki Y</u> , Arase Y, Kumada H	What Is the Most Effective Drug Delivery System for Cisplatin during the Treatment of Hepatic Tumors with Single-Session Transcatheter Chemotherapy? A Pilot Study.	Gut Liver	5	576-584	2013
Hara T, Akuta N, Suzuki F, Sezaki H, <u>Suzuki Y</u> , Hosaka, Kobayashi M, Saitoh, Kumada H.	A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic Hepatitis C.	J Med Virol	85	1746-1753	2013
Kobayashi M, Hosaka T, Suzuki F, Akuta N, Sezaki H, <u>Suzuki Y</u> , Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H.	Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up.	J Gastroenterol		In press	
Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, <u>Suzuki Y</u> , Arase Y, Kumada H.	Transcatheter arterial chemotherapy with miriplatin for hepatocellular carcinoma patients with chronic renal failure: report of three cases.	Gut Liver	7	246-251	2013
Ogura S, Saitoh S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki F, <u>Suzuki Y</u> , Arase Y, Ikeda K, Kumada H.	Magnetic resonance laparoscopy: A new non-invasive technique for the assessment of chronic viral disease.	Hepatol Res	43	836-845	2013

Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, <u>Suzuki Y</u> , Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis.	Intervirolgy	56	37-45	2013
Seko Y, Akuta N, Suzuki F, Kawamura Y, Sezaki H, Sezaki H, <u>Suzuki Y</u> , Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K. Kumada H.	Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy.	Intervirolgy	56	13-21	2013
Harada K, Kakuda Y, <u>Nakamura M</u> , <u>Shimoda S</u> , <u>Nakanuma Y</u> .	Clinicopathological significance of serum fractalkine in primary biliary cirrhosis.	Dig Dis Sci	58	3037-43	2013
Inamine T, Higa S, Noguchi F, Kondo S, Omagari K, Yatsushashi Y, Tsukamoto K, <u>Nakamura M</u> .	Association of genes involved in bile acid synthesis with the progression of primary biliary cirrhosis.	J Gastroenterol	48	1160-1170	2013
The Intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan, Working Subgroup(English version) for ClinicalPractice Guidelines for Primary Biliary Cirrhosis.	Guidelines for the management of primary biliary cirrhosis.	Hepatol Res	44 (Suppl. 1)	71-90	2014
廣原淳子, 仲野俊成, 關 壽人, 岡崎和一, 中沼安二, 坪内博仁	原発性胆汁性肝硬変 (PBC) 全国調査にみる本邦 PBC の病態と予後の変遷	日本消化器病学会雑誌	110(1)	8-15	2013
小森敦正, <u>石橋大海</u> , 中村 稔, 八橋 弘	原発性胆汁性肝硬変の予後	肝胆膵	66	455-461	2013
相葉佳洋, 小森敦正, 長岡進矢, 阿比留正剛, 右田清志, 伊東正博, <u>石橋大海</u> , 八橋 弘, 中村 稔	自己免疫性肝胆膵疾患の病態解明の進歩. 原発性胆汁性肝硬変患者における TL1A と DcR3の臨床学的意義	消化器と免疫	49	15-17	2013
<u>石橋大海</u> , 小森敦正	原発性胆汁性肝硬変 (PBC) の診療ガイドライン	消化器の臨床	16(2)	117-122	2013
<u>石橋大海</u> , <u>下田慎治</u> , 中村 稔	原発性胆汁性肝硬変の自己抗原は何か	分子消化器病	10	131-137	2013
<u>石橋大海</u> , <u>下田慎治</u> , 中村 稔	【自己免疫疾患・アレルギー疾患 (後篇) それぞれの疾患の理解】臓器特異的自己免疫疾患 原発性胆汁性肝硬変	最新医学増刊号	68(6)	1326-1334	2013
中村 稔	PBC の疾患感受性遺伝子による病態の解明	日本消化器病学会雑誌	110	1602-1610	2013

下田慎治, 中村 稔, 石橋大海	PBC の発症機序	肝臓	54(10)	676-681	2013
石橋大海	【稀少疾患】 原発性胆汁性肝硬変. ケアネット CareNet			<a href="http://www.carenet.com/">http://www.carenet.com/</a>	2014
石橋大海, 小森敦正	UDCA 使用中の原発性胆汁性肝硬変 (PBC) 患者に対するベザフィブラートの併用効果	Minds トピックス			2014
大平弘正, 原田憲一, 下田慎治, 中村 稔	PBC 最近の話題	日本消化器病学会雑誌	110	29-43	2013
中村 稔	ゲノムワイド関連解析による日本人原発性胆汁性肝硬変の疾患感受性遺伝子, <i>TNFSF15</i> , <i>POU2AF1</i> の同定	分子消化器病	10(1)	85-89	2013
中村 稔	PBC の治療反応性と予後予測 —厚生労働省研究班による多施設の PBC 研究成果—	たんじゅうさん	12(2)	16-117	2013
中村 稔, 西田奈央, 川嶋実苗, 相葉佳洋, 小森敦正, 八橋 弘, 徳永勝士, 国立病院機構 肝ネットワーク PBC 研究班, 厚生労働省難 治性疾患克服研究事業・ 難治性の肝胆膵疾患に 関する調査研究班	原発性胆汁性肝硬変 (PBC) の疾患感受性遺伝子による病態の解明	第20回浜名湖シンポジウム記録集 ゲノム情報の臨床 応用		74-78	2013
相葉佳洋, 小森敦正, 長岡進矢, 阿比留正剛, 右田清志, 伊東正博, 石橋大海, 八橋 弘, 中村 稔	原発性胆汁性肝硬変患者における TL1A と DcR3 の臨床学的意義	消化器と免疫	49	15-17	2013
原田憲一, 中村 稔, 下田慎治, 中沼安二	原発性胆汁性肝硬変における血中 Fractalkine の意義	消化器と免疫	49	12-14	2013
Aiba Y, Nakamura M.	The role of TL1A and DR3 in autoimmune and inflammatory diseases.	Mediators Inflamm		In press	
Aiba Y, Harada K, Komori A, Ito M, Shimoda S, Nakamura H, Nagaoka S, Abiru S, Migita K, Ishibashi H, Nakanuma Y, Nishida N, Kawashima M, Tokunaga K, Yatsuhashi H, Nakamura M.	Systemic and local expression levels of TNF-like ligand 1A and its decoy receptor 3 are increased in primary biliary cirrhosis.	Liver Int		In press	
Harada K, Kakuda Y, Nakamura M, Shimoda S, Nakanuma Y.	Clinicopathological significance of serum fractalkine in primary biliary cirrhosis	Dig Dis Sci	58	3037-43	2013
Ohishi Y, Nakamura M, Ishikawa N, Saitoh O, Nakamura H, Aiba Y, Komori A, Migita K, Yatsuhashi H, Fukushima N, Kohjima M, Yoshimoto T, Fukuizumi K, Ishibashi M, Nishino T, Shirabe K, Taketomi A, Maehara Y, Ishibashi H, Nakamura M ; PBC Study Group of NHOSLJ.	Genetic polymorphisms of OCT-1 confer susceptibility to severe progression of primary biliary cirrhosis in Japanese patients.	J Gastroenterol	49(2)	332-42	2014



田中 篤, 田妻 進, 岡崎和一, 坪内博仁, 乾 和郎, 滝川 一	硬化性胆管炎の全国調査	胆道	27(2)	176-187	2013
Tanaka, A, Takikawa H.	Geoepidemiology of primary sclerosing cholangitis: A critical review.	J Autoimmunity	46	35-40	2013
Tanaka A, Tazuma S, Okazaki K, Tsubouchi H, Inui K, Takikawa H.	Nationwide survey for primary sclerosing cholangitis and IgG4-related sclerosing cholangitis in Japan.	J Hepatobiliary Pancreat Sci	21	43-50	2014
Harada K, Hsu M, Ikeda H, Zeniya M, Nakanuma Y.	Application and Validation of a New Histologic Staging and Grading System for Primary Biliary Cirrhosis.	J Clin Gastroenterol	47(2)	174-81	2013
Kakuda Y, Harada K, Sawada-Kitamura S, Ikeda H, Sato Y, Sasaki M, Okafuji H, Mizukoshi E, Terasaki S, Ohta H, Kasashima S, Kawashima A, Kaizaki Y, Kaneko S, Nakanuma Y.	Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems.	Hum Pathol	44(6)	1107-17	2013
Okamura A, Harada K, Nio M, Nakanuma Y.	Participation of natural killer cells in the pathogenesis of bile duct lesions in biliary atresia.	J Clin Pathol	66(2)	99-108	2013
Nozaki Y, Harada K, Sanzen T, Nakanuma Y.	PPAR $\gamma$ ligand attenuates portal inflammation in the MRL-lpr mouse: a new strategy to restrain cholangiopathy in primary biliary cirrhosis.	Med Mol Morphol	46(3)	153-9	2013
Okamura A, Harada K, Nio M, Nakanuma Y.	Interleukin-32 production associated with biliary innate immunity and proinflammatory cytokines contributes to the pathogenesis of cholangitis in biliary atresia.	Clin Exp Immunol	173(2)	268-75	2013
Harada K, Hirohara J, Ueno Y, Nakano T, Kakuda Y, Tsubouchi H, Ichida T, Nakanuma Y.	Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: National data from Japan.	Hepatology	57(5)	Sep-42	2013
Harada K, Kakuda Y, Nakamura M, Shimoda S, Nakanuma Y.	Clinicopathological significance of serum fractalkine in primary biliary cirrhosis.	Dig Dis Sci	58(10)	3037-43	2013
Harada K, Nakanuma Y.	Prevalence and risk factors of hepatocellular carcinoma in Japanese patients with primary biliary cirrhosis.	Hepatol Res	44(2)	133-40	2014
Harada K, Kakuda Y, Sato Y, Ikeda H, Shimoda S, Yamamoto Y, Inoue H, Ohta H, Kasashima S, Kawashima A, Nakanuma Y.	Alteration of energy metabolism in the pathogenesis of bile duct lesions in primary biliary cirrhosis.	J Clin Pathol		In press	
原田憲一, 中沼安二	原発性胆汁性肝硬変の新しい病期分類・活動度分類	病理と臨床	31(2)	210-12	2013
角田優子, 齊川邦和, 松下信之, 原田憲一, 中沼安二	< 短報 > オルセイン染色の実態調査結果と標準化への試み	肝臓	54(10)	716-9	2013

Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Maruyama T, Tanabe Y, Satoh T, <u>Nakamuta M</u> , Kotoh K, Azuma K, Dohmen K, <u>Shimoda S</u> , Hayashi J ; Kyushu University Liver Disease Study (KULDS) Group.	Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: A prospective, multicenter study.	J Hepatol	58(3)	495-501	2013
Ikegami T, Shirabe K, Fukuhara T, Furusyo N, Kotoh K, Kato M, <u>Shimoda S</u> , Aishima S, Soejima Y, Yoshizumi T, <u>Maehara Y</u> .	Early extensive viremia, but not rs8099917 genotype, is the only predictor for cholestatic hepatitis C after living-donor liver transplantation.	Hepatol Res	43(6)	621-9	2013
Ikegami T, Shirabe K, Yoshizumi T, Furusyo N, Kotoh K, Kato M, <u>Shimoda S</u> , Soejima Y, Motomura T, Fukuhara T, <u>Maehara Y</u> .	Impact of conversion from pegylated interferon- a 2b to interferon- a 2a for treating recurrent hepatitis C after liver transplantation.	Transplantation	95(6)	e38-42	2013
Furusyo N, Ogawa E, <u>Nakamuta M</u> , Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, <u>Shimoda S</u> , Hayashi J.	Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.	J Hepatol	59(2)	205-212	2013
Ogawa E, Furusyo N, <u>Nakamuta M</u> , Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, <u>Shimoda S</u> , Hayashi J.	Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.	J Hepatol	59(4)	667-74	2013
Sumida K, <u>Shimoda S</u> , Iwasaka S, Hisamoto S, Kawanaka H, Akahoshi T, Ikegami T, Shirabe K, Shimono N, <u>Maehara Y</u> , Selmi C, Gershwin ME, Akashi K.	Characteristics of Splenic CD8 <sub>+</sub> T Cell Exhaustion in Patients with Hepatitis C.	Clin Exp Immunol	174(1)	172-8	2013
Honda A, Ikegami T, <u>Nakamuta M</u> , Miyazaki T, Iwamoto J, Hirayama T, Saito Y, <u>Takikawa H</u> , Imawari M, <u>Matsuzaki Y</u> .	Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.	Hepatology	57	1931-1941	2013
Tanaka T, Yamashiki N, Sugawara Y, Tamura S, <u>Nakamura M</u> , Kaneko J, Aoki T, Sakamoto Y, Hasegawa K, <u>Kokudo N</u> .	Chronologic changes of explanted liver volume and the use of ursodeoxycholic acid in patients with end-stage primary biliary cirrhosis.	Hepatol Res		In press	

Tanaka T, Sugawara Y, Tamura S, Kaneko J, Takazawa Y, Aoki T, Hasegawa K, Sakamoto Y, Yamashiki N, <u>Kokudo N.</u>	Living donor liver transplantation for non-alcoholic steatohepatitis: A single center experience.	Hepatol Res		In press	
Kaneko J, Sugawara Y, Tamura S, Aoki T, Sakamoto Y, Hasegawa K, Yamashiki N, <u>Kokudo N.</u>	De novo malignancies after adult-to-adult living-donor liver transplantation with a malignancy surveillance program: comparison with a Japanese population-based study.	Transplantation	95	1142-7	2013
Ijichi H, Shirabe K, Taketomi A, Yoshizumi T, Ikegami T, Mano Y, Aishima S, Abe K, Honda H, <u>Maehara Y.</u>	Clinical usefulness of (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for patients with primary liver cancer with special reference to rare histological types, hepatocellular carcinoma with sarcomatous change and combined hepatocellular and cholangiocarcinoma.	Hepatol Res	43(5)	481-7	2013
Yoshiya S, Shirabe K, Matsumoto Y, Ikeda T, Soejima Y, Yoshizumi T, Uchiyama H, Ikegami T, Harimoto N, <u>Maehara Y.</u>	Rendezvous ductoplasty for biliary anastomotic stricture after living-donor liver transplantation.	Transplantation	95(10)	1278-83	2013
Ikegami T, Shirabe K, Nakagawara H, Yoshizumi T, Toshima T, Soejima Y, Uchiyama H, Yamashita Y, Harimoto N, <u>Maehara Y.</u>	Obstructing spontaneous major shunt vessels is mandatory to keep adequate portal inflow in living-donor liver transplantation.	Transplantation	95(10)	1270-7	2013
Yoshizumi T, Ikegami T, Yoshiya S, Motomura T, Mano Y, Muto J, Ikeda T, Soejima Y, Shirabe K, <u>Maehara Y.</u>	Impact of tumor size, number of tumors and neutrophil-to-lymphocyte ratio in liver transplantation for recurrent hepatocellular carcinoma.	Hepatol Res	43(7)	709-16	2013
Ikegami T, Shirabe K, Yoshiya S, Soejima Y, Yoshizumi T, Uchiyama H, Toshima T, Motomura T, <u>Maehara Y.</u>	One-step reconstruction of the right inferior hepatic veins using auto-venous grafts in living-donor liver transplantation.	Surg Today	43(7)	769-76	2013
Morita K, Shirabe K, Yoshizumi T, Ikegami T, Masuda T, Hashimoto N, Mano Y, Miyata T, Soejima Y, <u>Maehara Y.</u>	Feasible isolated liver transplantation for a cirrhotic patient on chronic hemodialysis.	Case Rep Gastroenterol	7(2)	299-303	2013
Toshima T, Shimada M, Ikegami T, Utsunomiya T, Ikemoto T, Morine Y, Yoshizumi T, Soejima Y, Shirabe K, <u>Maehara Y.</u>	Fairly rare spontaneous disappearance of a hepatic artery aneurysm following living donor liver transplantation.	Liver Transpl	19(8)	929-30	2013
Ikegami T, Imai D, Wang H, Yoshizumi T, Yamashita YI, Ninomiya M, Iguchi T, Bekki Y, Shirabe K, <u>Maehara Y.</u>	D-MELD as a Predictor of Early Graft Mortality in Adult-to-Adult Living-Donor Liver Transplantation.	Transplantation	97(4)	457-62	2014

Matsumoto Y, Ikegami T, Morita K, Yoshizumi T, Kayashima H, Shirabe K, <u>Maehara Y.</u>	Renoportal anastomosis in right lobe living donor liver transplantation: report of a case.	Surg Today	43(11)	1316-20	2013
Yoshizumi T, Ikegami T, Toshima T, Harimoto N, Uchiyama H, Soejima Y, Yamashita Y, Shirabe K, <u>Maehara Y.</u>	Two-step selection criteria for living donor liver transplantation in patients with hepatocellular carcinoma.	Transplant Proc	45(9)	3310-3	2013
Harimoto N, Shirabe K, Nakagawara H, Toshima T, Yamashita Y, Ikegami T, Yoshizumi T, Soejima Y, Ikeda T, <u>Maehara Y.</u>	Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio.	Transplantation	96(11)	1008-12	2013
Renzi A, DeMorrow S, Onori P, Carpino G, Mancinelli R, Meng F, Venter J, White M, Franchitto A, Francis H, Han Y, <u>Ueno Y.</u> Dusio G, Jensen KJ, Greene JJ, Jr., Glaser S, Gaudio E, Alpini G.	Modulation of the biliary expression of arylalkylamine N-acetyltransferase alters the autocrine proliferative responses of cholangiocytes in rats.	Hepatology	57(3)	1130-41	2013
Ninomiya M, Kondo Y, Funayama R, Nagashima T, Kogure T, Kakazu E, Kimura O, <u>Ueno Y.</u> Nakayama K, Shimosegawa T.	Distinct microRNAs expression profile in primary biliary cirrhosis and evaluation of miR 505-3p and miR197-3p as novel biomarkers.	PloS One	8(6)	e66086	2013
Mancinelli R, Franchitto A, Glaser S, Meng F, Onori P, Demorrow S, Francis H, Venter J, Carpino G, Baker K, Han Y, <u>Ueno Y.</u> Gaudio E, Alpini G.	GABA induces thee differentiation of small into large cholangiocytes by activation of Ca(2+) /CaMK I-dependent adenylyl cyclase 8.	Hepatology	58(1)	251-63	2013
Osawa Y, Suetsugu A, Matsushima-Nishiwaki R, Yasuda I, <u>Saibara T.</u> Moriwaki H, Seishima M, Kozawa O.	Liver acid sphingomyelinase inhibits growth of metastatic colon cancer.	J Clin Invest	123	834-843	2013
Ue M, Ikebe N, Munekage K, Ochi T, Ono M, <u>Saibara T.</u>	Hepatocyte destruction with enhanced collagen synthesis in the liver of chronic hepatitis C patients on hemodialysis.	J Viral Hepat	20	350-357	2013
Osawa Y, Hoshi M, Yasuda I, <u>Saibara T.</u> Moriwaki H, Kozawa O.	Tumor necrosis factor- $\alpha$ promotes cholestasis-induced liver fibrosis in the mouse through tissue inhibitor of metalloproteinase-1 production in hepatic stellate cells.	PLoS One	8	e65251	2013

Yoneda M, Imajo K, Eguchi Y, Fujii H, Sumida Y, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Aoki N, Sata M, Kanemasa K, Kohgo Y, <u>Saibara T</u> , Chayama K, Itoh Y, Yoshikawa T, Anzai K, Fujimoto K, Okanoue T, Nakajima A; Japan Study Group of Nonalcoholic Fatty Liver Disease.	Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels.	J Gastroenterol	48	1051-1060	2013
<u>Saibara T</u> , Enomoto N, Kaneko S, Chayama K, Sata M, Imawari M, Onishi S, Okita K.	Clinical efficacy of combination therapy with ME3738 and pegylated interferon alpha-2a in patients with hepatitis C virus genotype 1.	Hepatol Res		In press	
Ono M, Ogasawara M, Hirose A, Mogami S, Ootake N, Aritake K, Higuchi T, Okamoto N, Sakamoto S, Yamamoto M, Urade Y, <u>Saibara T</u> , Oben JA.	Bofutsushosan, a Japanese herbal (Kampo) medicine, attenuates progression of nonalcoholic steatohepatitis in mice.	J Gastroenterol		In press	
Hasegawa T, Yamao K, Hijioka S, Bhatia V, Mizuno N, Hara K, Imaoka H, Niwa Y, Tajika M, Kondo S, Tanaka T, Shimizu Y, Kinoshita T, Kohsaki T, Nishimori I, Iwasaki S, <u>Saibara T</u> , Hosoda W, Yatabe Y.	Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors.	Endoscopy	46	32-38	2014
Taketani H, Sumida Y, Tanaka S, Imajo K, Yoneda M, Hyogo H, Ono M, Fujii H, Eguchi Y, Kanemasa K, Chayama K, Itoh Y, Yoshikawa T, <u>Saibara T</u> , Fujimoto K, Nakajima A ; Japan Study Group of NAFLD	The association of insomnia with gastroesophageal reflux symptoms in biopsy-proven nonalcoholic fatty liver disease.	J Gastroenterol		In press	
Hashiba M, Ono M, Hyogo H, Ikeda Y, Masuda K, Yoshioka R, Ishikawa Y, Nagata Y, Munekage K, Ochi T, Hirose A, Nozaki-Fujimura Y, Noguchi S, Okamoto N, Chayama K, Suganuma N, <u>Saibara T</u> .	Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic Fatty liver disease.	PLoS One	8	e76161	2013

Toda K, Hayashi Y, Yamashita A, Okabe M, Ono M, <u>Saibara T</u> .	Aromatase-null mice expressing enhanced green fluorescent protein in germ cells provide a model system to assess estrogen-dependent ovulatory responses.	Transgenic Res		In press	
Nakahara T, Hyogo H, Yoneda M, Sumida Y, Eguchi Y, Fujii H, Ono M, Kawaguchi T, Imajo K, Aikata H, Tanaka S, Kanemasa K, Fujimoto K, Anzai K, <u>Saibara T</u> , Sata M, Nakajima A, Itoh Y, Chayama K, Okanou T; Japan Study Group of Nonalcoholic Fatty Liver Disease.	Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients.	J Gastroenterol		In press	
Tanaka K, Hyogo H, Ono M, Takahashi H, Kitajima Y, Ono N, Eguchi T, Fujimoto K, Chayama K, <u>Saibara T</u> , Anzai K, Eguchi Y, Japan Study Group of Nonalcoholic Fatty Liver Disease.	The upper limit of normal serum alanine aminotransferase levels in Japanese subjects.	Hepatol Res		In press	
越智経浩, 宗景玄祐, 小野正文, <u>西原利治</u>	非アルコール性脂肪肝 (NASH) の診療	臨床と研究	90	183-187	2013
<u>西原利治</u>	非アルコール性脂肪性肝疾患 (NASH / NAFLD)	日本臨床内科医学会誌	28	11-17	2013
<u>西原利治</u> , 羽柴 基, 小野正文	糖尿病と脂肪肝	Diabetes Frontier	24	408-411	2013
徳光敬太, 小野正文, <u>西原利治</u>	NAFLD/NASH の疫学		28	403-407	2013
宮本敬子, 小野正文, <u>西原利治</u>	非アルコール性脂肪性肝疾患の疾患関連遺伝子	日本消化器病学会雑誌	110	1597-1601	2013
十河 剛, 森實雅司, 乾あやの, 藤澤知雄	小児急性肝不全の内科的治療戦略	日本小児科学会誌	117(4)	718-731	2013
持田 智, 滝川康裕, 中山伸朗, 桶谷 真, 内木隆文, 山岸由幸, 藤原慶一, 市田隆文, <u>坪内博仁</u>	急性肝不全の成因分類	肝臓		印刷中	
藤原慶一, 織田成人, 井上和明, 荒田慎寿, 安部隆三, 滝川康裕, 井戸章雄, 持田 智, <u>坪内博仁</u> , 横須賀收	急性肝不全に対する人工肝補助療法についての提言: high-flow CHDF, on-line HDF による覚醒率向上の認識とその全国標準化の必要性	肝臓		印刷中	
<u>Mochida S</u> , Takikawa Y, Nakayama N, Oketani M, Naiki T, Yamagishi Y, Fujiwara K, <u>Ichida K</u> , <u>Tsubouchi H</u> .	Classification of the etiologies of acute liver failure in Japan: A report by the Intractable Hepato-Biliary Diseases Study Group of Japan.	Hepatol Res		In press	

Harigai M, <u>Mochida S</u> , Mimura T, Koike T, Miyasaka N.	A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy.	Mod Rheumatol	24	1-7	2014
Nakayama N, Oketani M, Kawamura Y, Inao M, Nagoshi S, Fujiwara K, <u>Tsubouchi H, Mochida S.</u>	Algorithm to determine the outcome of patients with acute liver failure: a data mining analysis using decision trees.	J Gastroenterol	47	664-677	2012
Sugawara K, Nakayama N, <u>Mochida S.</u>	Acute liver failure in Japan: definition, classification, and prediction of the outcome.	J Gastroenterol	47	849-861	2012
Fujiwara K, Yasui S, <u>Yokosuka O.</u>	Autoimmune acute liver failure: An emerging etiology for intractable acute liver failure. (Review).	Hepatol Int	7	335-346	2013
Fujiwara K, Yasui S, Yonemitsu Y, Mikata R, Arai M, Kanda T, Imazeki F, Oda S, <u>Yokosuka O.</u>	Efficacy of high-dose corticosteroid in the early stage of viral acute liver failure.	Hepatol Res		In press	
Fujiwara K, Ohtsuka M, <u>Yokosuka O.</u>	Radiological and histological heterogeneity in a case of autoimmune acute liver failure.	Clin Gastroenterol Hepatol		In press	
Fujiwara K, Yasui S, <u>Yokosuka O.</u>	Treatment of autoimmune acute liver failure beyond consensus guidelines.	Aliment Pharmacol Ther	38	1143-1144	2013
Fujiwara K, Seza K, Fukuda Y, Nakano M, <u>Yokosuka O.</u>	A case of primary biliary cirrhosis and autoimmune hepatitis overlap showing acute presentation and transient seropositivity for immunoglobulin G and anti-nuclear antibody.	Clin J Gastroenterol	6	465-469	2013
Fujiwara K, Yasui S, <u>Yokosuka O.</u>	Corticosteroid for severe acute exacerbation of chronic hepatitis B.	Eur J Gastroenterol Hepatol	25	1492	2013
Kato A, Tanaka H, Kawaguchi T, Kanazawa H, Iwasa M, <u>Sakaïda I,</u> <u>Moriwaki H,</u> Murawaki Y, <u>Suzuki K,</u> Okita K.	Nutritional management contributes to improvement in minimal hepatic encephalopathy and quality of life in patients with liver cirrhosis: A preliminary, prospective, open-label study.	Hepatol Res	43	452-458	2013
Takase HM, Itoh T, Ino S, Wang T, Koji T, Akira S, Takikawa Y, Miyajima A.	FGF7 is a functional niche signal required for stimulation of adult liver progenitor cells that support liver regeneration.	Genes Dev	27	169-181	2013
Takikawa Y, Harada M, Wang T, <u>Suzuki K.</u>	Usefulness and accuracy of the international normalized ratio and activity percent of prothrombin time in patients with liver disease.	Hepatol Res		In press	
Kakisaka K, <u>Takikawa Y.</u>	Elevation of serum cytokines preceding elevation of liver enzymes in a case of drug-induced liver injury.	Hepatol Res		In press	
Wang T, Takikawa Y, Watanabe A, Kakisaka K, Oikawa K, Miyamoto Y, <u>Suzuki K.</u>	Proliferation of mouse liver stem/progenitor cells induced by plasma from patients with acute liver failure is modulated by P2Y2 receptor-mediated JNK activation.	J Gastroenterol		In press	
滝川康裕 鈴木一幸	肝疾患 急性肝不全の予後	肝胆膵	66	391-393	2013
滝川康裕	急性肝不全の診断基準	Modern Physician	33	515-518	2013

Kochi T, Shimizu M, Terakura D, Baba A, Ohno T, Kubota M, Shirakami Y, Tsurumi H, Tanaka T, <u>Moriwaki H.</u>	Non-alcoholic steatohepatitis and preneoplastic lesions develop in the liver of obese and hypertensive rats: Suppressing effects of EGCG on the development of liver lesions.	Cancer Lett	342	60-69	2014
Shimizu M, Tanaka T, <u>Moriwaki H.</u>	Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis.	Semin Immunopathol	35	191-202	2013
Shiraki M, Nishiguchi Y, Saito M, Fukuzawa Y, Mizuta T, Kaibori M, Hanai T, Nishimura K, Shimizu M, Tsurumi H, <u>Moriwaki H.</u>	Nutritional status and quality of life in current patients with liver cirrhosis as assessed in 2007-2011.	Hepatol Res	43	106-112	2013
Nagano J, Shimizu M, Hara T, Shirakami Y, Kochi T, Nakamura N, Ohtaki H, Ito H, Tanaka T, Tsurumi H, Saito K, Seishima M, <u>Moriwaki H.</u>	Effects of indoleamine 2,3-dioxygenase deficiency on high-fat diet-induced hepatic inflammation.	PLoS One	8	e73404	2013
Baba A, Shimizu M, Ohno T, Shirakami Y, Kubota M, Kochi T, Terakura D, Tsurumi H, <u>Moriwaki H.</u>	Synergistic growth inhibition by acyclic retinoid and phosphatidylinositol 3-kinase inhibitor in human hepatoma cells.	BMC Cancer	13	465	2013
Takaguchi K, <u>Moriwaki H.</u> , Doyama H, Iida M, Yagura M, Shimada N, Kang M, Yamada H, Kumada H.	Effects of branched-chain amino acid granules on serum albumin level and prognosis are dependent on treatment adherence in patients with liver cirrhosis.	Hepatol Res	43	459-466	2013
Izumi N, Asahina Y, Kurosaki M, Yamada G, Kawai T, Kajiwara E, Okamura Y, Takeuchi T, Yokosuka O, Kariyama K, Toyoda J, Inao M, Tanaka E, <u>Moriwaki H.</u> , Adachi H, Katsushima S, Kudo M, Takaguchi K, Hiasa Y, Chayama K, Yatsunami H, Oketani M, Kumada H.	Inhibition of hepatocellular carcinoma by PegIFN $\alpha$ -2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study.	J Gastroenterol	48	382-390	2013
Genda T, <u>Ichida T.</u> , <u>Sakisaka S.</u> , Sata M, Tanaka E, Inui A, <u>Egawa H.</u> , Umeshita K, Furukawa H, Kawasaki S, Inomata Y.	Waiting list mortality of patients with primary biliary cirrhosis in the Japanese transplant allocation system.	J Gastroenterol	49(2)	324-31	2014
Kikuchi T, Hirano K, Genda T, Tsuzura H, Sato S, Kanemitsu Y, Iijima K, <u>Ichida T.</u>	A study of the effects of the saliva stimulation by nizatidine on dry mouth symptoms of primary biliary cirrhosis.	World J Hepatol	5	90-96	2013



Tsuzura H, Genda T, Sato S, Hirano K, Kanemitsu Y, Narita Y, Kikuchi T, Iijima K, Wada R, <u>Ichida T</u>	Association of visceral obesity with high viral load and histological finding in elderly patients with genotype 1 chronic hepatitis C.	Intern Med	52	1665-1673	2013
Narita Y, Genda T, Tsuzura H, Sato S, Kanemitsu Y, Ishikawa S, Kikuchi T, Hirano K, Iijima K, Wada R, <u>Ichida T</u> .	Prediction of liver stiffness for hepatocellular carcinoma in chronic hepatitis C patients on interferon-based anti-viral therapy.	J Gastroenterol Hepatol	29	137-143	2014
Nouso Y, Miyahara K, Uchida D, Kuwaki K, Izumi N, Omata M, <u>Ichida T</u> , Kudo M, Ku Y, <u>Kokudo N</u> , Sakamoto M, Nakashima O, Takayama T, Matsui O, Matsuyama Y, Yamamoto K.	Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan.	Br J Cancer	109	1904-1907	2013
Utsunomiya T, Shimada M, Kudo M, <u>Ichida T</u> , Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M. ; Liver Cancer Study Group of Japan.	Nationwide Study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact.	Ann Surg	259(2)	336-45	2014
Kanda T, Kato K, Tsubota A, Takada N, Nishino T, Mikami S, Miyamura T, Maruoka D, Wu S, Nakamoto S, Arai M, Fujiwara K, Imazeki F, <u>Yokosuka O</u> .	Platelet count and sustained virological response in hepatitis C treatment.	World J Hepatol	5	182-8	2013
Kamezaki H, Kanda T, Arai M, Wu S, Nakamoto S, Chiba T, Maruyama H, Fujiwara K, Kanai F, Imazeki F, Nomura F, <u>Yokosuka O</u>	Adherence to medication is a more important contributor to viral breakthrough in chronic hepatitis B patients treated with entecavir than in those with Lamivudine	Int J Med Sci	10	567-74	2013
Kanda T, Nakamoto S, Nishino T, Takada N, Tsubota A, Kato K, Miyamura T, Maruoka D, Wu S, Tanaka T, Arai M, Mikami S, Fujiwara K, Imazeki F, <u>Yokosuka O</u>	Peginterferon Alfa-2a plus ribavirin in Japanese patients infected with hepatitis C virus genotype 2 who failed previous interferon therapy.	Int J Med Sci	10	43-49	2013
Kodama T, Hikita H, Kawaguchi T, Saito Y, Tanaka S, Shigekawa M, Shimizu S, Li W, Miyagi T, Kanto T, Hiramatsu N, Tatsumi T, Takehara T.	The Bcl-2 homology 3 (BH3)-only proteins Bim and Bid are functionally active and restrained by anti-apoptotic B-cell CLL/lymphoma 2 (Bcl-2) family proteins in healthy liver.	J Biol Chem	288	30009-30018	2013

Kawaguchi T, Kodama T, Hikita H, Tanaka S, Shigekawa M, Nawa T, Shimizu S, Li W, Miyagi T, Hiramatsu N, Tatsumi T, <u>Takehara T.</u>	Carbamazepine promotes liver regeneration and survival in mice.	J Hepatol	59	1239-1245	2013
Ishida H, Kato T, Takehana K, Tatsumi T, Hosui A, Nawa T, Kodama T, Shimizu S, Hikita H, Hiramatsu N, Kanto T, Hayashi N, <u>Takehara T.</u>	Valine, the Branched-Chain Amino Acid, Suppresses Hepatitis C Virus RNA Replication but Promotes Infectious Particle Formation.	Biochem Biophys Res Commun	437	127-133	2013
Yoshio S, Kanto T, Kuroda S, Matsubara T, Higashitani K, Kakita N, Ishida H, Hiramatsu N, Nagano H, Sugiyama M, Murata K, Fukuhara T, Matsuura Y, Hayashi N, Mizokami M, <u>Takehara T.</u>	Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon- $\lambda$ in response to hepatitis C virus.	Hepatology	57	1705-1715	2013
Oketani M, <u>Ido A</u> , Nakayama N, Takikawa Y, Naiki T, Yamagishi Y, <u>Ichida T</u> , <u>Mochida S</u> , <u>Ohnishi S</u> , <u>Tsubouchi H</u> ; Intractable Hepato-Biliary Diseases Study Group of Japan.	Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: Summary of the annual nationwide survey between 2004 and 2009.	Hepatol Res	43(2)	97-105	2013
<u>井上和明</u>	ウイルス性急性肝炎, 劇症肝炎の治療	Modern Physician	33	470-473	2013
<u>井上和明</u>	急性肝不全へ移行する可能性のある症例の見分け方とその治療	成人病と生活習慣病	43	1342-1346	2013
<u>井上和明</u> , 与芝真彰	HCV core 蛋白BASIC AMINO ACID REGION 1の持続感染成立における役割	肝臓	54	A234	2013
<u>井上和明</u> , 小原道法	急性肝不全, 劇症肝炎の近年の傾向と今後の治療対策	肝臓	54	A249	2013
<u>井上和明</u> , 与芝真彰	人工肝補助療法と原病治療からみた急性肝不全の病態理解	肝臓	54	A514	2013
<u>Inoue K.</u>	The intensive artificial liver support systems improves survival rate of FHF and makes perioperative management more appropriate	J Hepatol	58	S412	2013
<u>Inoue K</u> , Kohara M.	Hepatitis C virus core protein basic amino acid region 1 is responsible for the impairment of IRF-3 activation	J Hepatol	58	S471	2013
<u>Inoue K.</u>	Impairment of interferon regulatory factor-3 activation by hepatitis C virus core protein basic amino acid region 1.	Hepatol Int	7	S35	
Iwamoto T, Terai S, Hisanaga T, Takami T, Yamamoto N, Watanabe S, Sakaida I.	Bone-marrow-derived cells cultured in serum-free medium reduce liver fibrosis and improve liver function in carbon-tetrachloride-treated cirrhotic mice.	Cell Tissue Res	351(3)	487-495	2013

鈴木 裕, 森 俊幸, 横山政明, 中里徹矢, 阿部展次, 杉山政則	肝内結石症診療の現況 全国調査からみた肝 内結石症の現況	胆と膵	34	1119-1124	2013
佐田尚宏, 遠藤和洋, 小泉 大, 笹沼英紀, 安田是和.	【胆管癌のリスクファクター】肝内結石症の 全国調査からみた肝内胆管癌のリスク	胆と膵	34	465-468	2013
佐田尚宏, 遠藤和洋, 小泉 大, 笹沼英紀, 安田是和.	【肝内結石症診療の現状】肝内結石症の画像 診断	胆と膵	34	1159-1164	2013
遠藤和洋, 佐田尚宏, 田口昌延, 兼田裕司, 小泉 大, 笹沼英紀, 佐久間康成, 清水 敦, 俵藤正信, 安田是和.	Virtual 3D model, real 3D model による胆膵 手術シミュレーション並びにナビゲーション の試み	胆と膵	34	69-73	2013
小泉 大, 佐田尚宏, 安田是和.	膵臓と胆嚢・胆管疾患の診断と治療：アップ デート「胆石症, 胆嚢炎, Lemmel 症候群」	診断と治療	101	755-759	2013
Komeda K, Hayashi M, Inoue Y, Shimizu T, Asakuma M, Hirokawa F, Miyamoto Y, Uchiyama K.	Clinical usefulness of endo intestinal clips during Pringle's maneuver in laparoscopic liver resection: a technical report.	Surg Laparosc Endosc Percutan Tech	23	103-105	2013
Hirokawa F, Hayashi M, Miyamoto Y, Asakuma M, Shimizu T, Komeda K, Inoue Y, Uchiyama K, Nishimura Y.	Evaluation of postoperative antibiotic prophylaxis after liver resection: a randomized controlled trial.	Am J Surg	206	8-15	2013
Masubuchi S, Takai S, Jin D, Tashiro K, Komeda K, Li ZL, Otsuki Y, Okamura H, Hayashi M, Uchiyama K.	Chymase inhibitor ameliorates hepatic steatosis and fibrosis on established non- alcoholic steatohepatitis in hamsters fed a methionine- and choline-deficient diet.	Hepatol Res	43	970-8	2013
Inoue Y, Hayashi M, Tanaka R, Komeda K, Hirokawa F, Uchiyama K.	Short-term results of laparoscopic versus open liver resection for liver metastasis from colorectal cancer: a comparative study.	Am Surg	79	495-501	2013
Hirokawa F, Hayashi M, Miyamoto Y, Asakuma M, Shimizu T, Komeda K, Inoue Y, Uchiyama K.	Outcomes and predictors of microvascular invasion of solitary hepatocellular carcinoma.	Hepatol Res		In press	
内山和久	肝内結石症に対する外科手術	胆と膵	34	1183-86	2013
朝隈光弘, 井上善博, 米田浩二, 廣川文鋭, 宮本好晴, 林 道廣, 内山和久	消化器外科手術アトラス 単孔式腹腔鏡下肝 外側区域切除術 (図説)	消化器外科	36	1547-1557	2013
露口利夫, 杉山晴俊, 酒井裕司, 西川貴雄, 坂本 大, 中村昌人, 伊藤禎浩, 大山 広, 渡辺悠人, 三方林太郎, 酒井裕司, 横須賀収	無症状肝内結石症の予後と治療適応について	胆と膵	34(11)	1139-1142	2013
Hsu M, Sasaki M, Igarashi S, Sato Y, Nakanuma Y.	KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas.	Cancer	119	1669-1674	2013

Sasaki M, Matsubara T, Yoneda N, Nomoto K, Tsuneyama K, Sato Y, <u>Nakanuma Y.</u>	Overexpression of enhancer of zeste homolog 2 and MUC1 may be related to malignant behaviour in intraductal papillary neoplasm of the bile duct.	Histopathology	62	446-457	2013
Sato Y, Harada K, Sasaki M, <u>Nakanuma Y.</u>	Histological characteristics of biliary intraepithelial neoplasia-3 and intraepithelial spread of cholangiocarcinoma.	Virchows Arch	462	421-427	2013
Gandou C, Harada K, Sato Y, Igarashi S, Sasaki M, Ikeda H, <u>Nakanuma Y.</u>	Hilar cholangiocarcinoma and pancreatic ductal adenocarcinoma share similar histopathologies, immunophenotypes, and development-related molecules.	Hum Pathol	44	811-821	2013
Sato Y, Sasaki M, Harada K, Aishima S, Fukusato T, Ojima H, Kanai Y, Kage M, <u>Nakanuma Y, Tsubouchi H.</u>	Pathological diagnosis of flat epithelial lesions of the biliary tract with emphasis on biliary intraepithelial neoplasia.	J Gastroenterol	49	64-72	2014
Sato Y, Harada K, Sasaki M, <u>Nakanuma Y.</u>	Clinicopathological significance of S100 protein expression in cholangiocarcinoma.	J Gastroenterol Hepatol	28	1422-1429	2013
Igarashi S, Sato Y, Ren XS, Harada K, Sasaki M, <u>Nakanuma Y.</u>	Participation of peribiliary glands in biliary tract pathophysiology.	World J Hepatol	5	425-432	2013
Sato H, Sato Y, Harada K, Sasaki M, Hirano K, <u>Nakanuma Y.</u>	Metachronous intracystic and intraductal papillary neoplasms of the biliary tree.	World J Gastroenterol	19	6125-6126	2013
Sasaki M, Matsubara T, Nitta T, Sato Y, <u>Nakanuma Y.</u>	GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct.	PLoS One	8	e81706	2013
中沼安二, 佐々木素子, 佐藤保則.	早期胆道癌（胆嚢と胆管）の分子病理	肝胆膵	66	171-180	2013
佐々木素子, 中沼安二.	K-ras.	臨床検査	57	256-261	2013
佐藤保則, 中沼安二.	胆管内乳頭腫瘍（IPNB）と胆管上皮腫瘍性病変（BiIIN）の診断と意義	病理と臨床	31	237-244	2013
中西喜嗣, 中沼安二, 河上 洋, 松本 譲, 新田健雄, 佐藤保則, 平野 聡.	IPMN と IPNB：前腸由来臓器に発生する乳頭状腫瘍の疾患理解	肝胆膵	66	691-700	2013
中沼安二, 佐藤保則.	胆管・胆嚢の組織学的基礎 - 胆管での粘液産生と胆管周囲付属腺について	胆と膵	34	347-352	2013
中沼安二, 佐々木素子, 佐藤保則, 原田憲一.	胆道癌の病理診断	消化器外科	36	1097-1108	2013
佐藤保則, 中沼安二.	肝内結石症の胆道発癌—病理学的立場から	胆と膵	34	1145-1152	2013
正田純一	疾病予防・健康増進のための分子スポーツ医学 肝疾患と分子スポーツ医学	医学のあゆみ	244	934-938	2013
正田純一	胆道癌, 肝内胆管癌のリスクファクターとその発癌・進展の分子メカニズム	胆と膵	34	455-460	2013
正田純一	Science of Kampo View インチンコウ湯	漢方医学	37	194-197	2013
正田純一	日本胆道学会認定指導医養成講座 胆石の種類と成因 第48回日本胆道学会学術集会記録	胆道	27	672-679	2013
正田純一	肝内結石症の胆道発癌 - 分子生物学の立場から -	胆と膵	34	1153-1158	2013